Evidence map›Paper›PMID 41165854›Full record

ReviewHerzschrittmachertherapie & Elektrophysiologie2025

[Leadless cardiac pacemaker : Overview, tips, and tricks].

Arian Sultan, David Duncker, Henning Jansen, Micaela Ebert, Victoria Johnson, Till Althoff, Tillmann Maurer, Sascha Rolf, Christian Heeger, Heidi Estner and 8 more

Erratum issuedAbstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Herzschrittmachertherapie & Elektrophysiologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Erratum issued
    2026
5 · Who and what money

Authors and funding

18 authors.

Arian SultanSt. Georg Herzzentrum Hamburg, Asklepios Klinik Hamburg, Lohmühlenstraße 5, 20099, Hamburg, Deutschland. a.sultan@asklepios.com.
David DunckerHannover Herzrhythmus Centrum, Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
Henning JansenElektrophysiologie Bremen, Herzzentrum Bremen am Klinikum Links der Weser, Bremen, Deutschland.
Micaela EbertSektion Rhythmologie, Klinik für Innere Medizin und Kardiologie, Herzzentrum Dresden, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland.
Victoria JohnsonUniversitäres Herz- und Gefäßzentrum Frankfurt, ZIM III, Universitätsmedizin Frankfurt, Frankfurt, Deutschland.
Till AlthoffAngiologie und Intensivmedizin, Deutsches Herzzentrum der Charité (DHZC) Klinik für Kardiologie, Berlin, Deutschland.
Tillmann MaurerAsklepios Klinik Nord Heidberg, Hamburg, Deutschland.
Sascha RolfDRK Kliniken Berlin Westend, Med. Klinik für Innere Medizin m.S. Kardiologie, Berlin, Deutschland.
Christian HeegerDepartment Elektrophysiologie, Asklepios Klinik Altona, Hamburg, Deutschland.
Heidi EstnerMedizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Deutschland.
Andreas RilligUniversitäres Herz- und Gefäßzentrum Hamburg Eppendorf, UKE, Hamburg, Deutschland.
Philipp SommerKlinik für Elektrophysiologie und Rhythmologie, Herz- und Diabeteszentrum NRW, Ruhr Universität Bochum, Bad Oeynhausen, Deutschland.
Leon IdenSegeberger Kliniken, Bad Segeberg, Deutschland.
K R Julian ChunCardioangiologisches Centrum Bethanien, Med. Klinik III, Markuskrankenhaus Frankfurt am Main, Frankfurt am Main, Deutschland.
Sonia BuschAbteilung Elektrophysiologie, Herz-Zentrum Bodensee, Konstanz, Deutschland.
Roland TilzKlinik für Rhythmologie Uniklinik Lübeck, UKSH, Lübeck, Deutschland.
Tillmann DahmeKlinik für Kardiologie, Angiologie, Pneumologie, Klinikum Esslingen, Esslingen, Deutschland.
Daniel StevenAbt. für Elektrophysiologie, Herzzentrum der Universität zu Köln, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leadless pacemakers (LP) have emerged as a validated alternative to conventional transvenous systems, offering significant complication reduction by eliminating leads and device pockets. Current LP technologies include the Micra™ series (Medtronic, Minneapolis, MN, USA) and the modular Aveir™ system (Abbott Laboratories, Abbott Park, IL, USA), enabling the first fully leadless dual-chamber pacing. Clinical benefits are most evident in patients at high infection risk or with venous access limitations. Advances such as atrioventricular (AV)-synchronous pacing and long battery life have broadened indications, while maintaining stable device performance. Key challenges remain in end-of-life management and guideline integration. Future directions may involve combinations with subcutaneous implantable cardioverter-defibrillators (ICDs) or energy-harvesting technologies, further expanding therapeutic applications.

Indexed as

Arrhythmias, CardiacPacemaker, ArtificialEquipment DesignEquipment Failure AnalysisHumansBattery life leadless pacingCapsule pacemakerImplantation leadless pacingModern pacemaker therapyTips and tricks leadless pacing

Identifiers

PMID41165854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.